Skip to main content

Clinical Trials | A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not been treated previously. The purposes of this study is to see if nemtabrutinib (MK1026) is effective in treating your CLL or SLL. The trial will compare nemtabrutinib to 2 other standard of care treatments for CLL and SLL, ibrutinib and acalabrutinib. The drug you receive in this study will depend on which group you are placed in. This trial has two groups: • Group 1: will receive nemtabrutinib • Group 2: will receive ibrutinib or acalabrutinib A computer will decide which group you are put in. You have an equal chance of being put in either group 1 or group 2. You, your trial doctor, and the trial staff will know what you are getting. If you are in Group 2, the trial doctor will decide if you will get ibrutinib or acalabrutinib. Nemtabrutinib, ibrutinib, and acalabrutinib are taken by mouth. Nemtabrutinib is a tablet. Ibrutinib and acalabrutinib may be either tablets or capsules. You will receive treatment as long as your cancer does not progress, you are tolerating the trial drug, and you have not started any new treatment for your cancer. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT06136559 [email protected]